BETHESDA, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, announced that its recent study, “A Randomized Study of Lubiprostone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain,” has been published online in the medical journal, Pain Medicine. The study examines the efficacy and safety of AMITIZA ® (oral lubiprostone) for relieving symptoms of opioid-induced constipation (OIC) in chronic non-cancer pain.
Help employers find you! Check out all the jobs and post your resume.
